{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T11:22:02Z","timestamp":1725708122937},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","journalofsurgicalresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jss.2018.04.040","type":"journal-article","created":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T18:21:17Z","timestamp":1527272477000},"page":"71-79","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The impact of aspirin use on breast cancer subtype and clinical course"],"prefix":"10.1016","volume":"230","author":[{"given":"Austin D.","family":"Williams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun R.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alycia","family":"So","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Steel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Carrigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Ro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Tchou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jss.2018.04.040_bib1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.7326\/M15-2113","article-title":"Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services task force","volume":"164","author":"Guirguis-Blake","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jss.2018.04.040_bib2","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jss.2018.04.040_bib3","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","article-title":"Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jss.2018.04.040_bib4","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jss.2018.04.040_bib5","series-title":"Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]","author":"Chubak","year":"2015"},{"key":"10.1016\/j.jss.2018.04.040_bib6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0140-6736(77)92496-5","article-title":"Prostaglandins and breast cancer","volume":"2","author":"Bennett","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.jss.2018.04.040_bib7","first-page":"2997","article-title":"The aspirin metabolite salicylate inhibits breast cancer cells growth and their synthesis of the osteolytic cytokines interleukins-6 and -11","volume":"19","author":"Sotiriou","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jss.2018.04.040_bib8","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/bjc.1983.251","article-title":"Prostaglandins in breast cancer: relationship to disease stage and hormone status","volume":"48","author":"Karmali","year":"1983","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2018.04.040_bib9","first-page":"5125","article-title":"Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines","volume":"56","author":"Liu","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.jss.2018.04.040_bib10","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1001\/jama.291.20.2433","article-title":"Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk","volume":"291","author":"Terry","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jss.2018.04.040_bib11","first-page":"625","article-title":"Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in\u00a0vivo","volume":"62","author":"Leahy","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.jss.2018.04.040_bib12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0092-8674(95)90127-2","article-title":"Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2","volume":"83","author":"Tsujii","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.jss.2018.04.040_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3004","article-title":"Contribution of platelets to tumour metastasis","volume":"11","author":"Gay","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jss.2018.04.040_bib14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/jcp.55.6.429","article-title":"Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer","volume":"55","author":"Costa","year":"2002","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jss.2018.04.040_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00432-003-0459-1","article-title":"Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis","volume":"129","author":"Wulfing","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jss.2018.04.040_bib16","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1002\/cncr.11437","article-title":"Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma","volume":"97","author":"Denkert","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jss.2018.04.040_bib17","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.ejso.2006.05.010","article-title":"Cox-2 expression on tissue microarray of breast cancer","volume":"32","author":"Park","year":"2006","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jss.2018.04.040_bib18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10549-011-1651-7","article-title":"COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin","volume":"130","author":"Holmes","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jss.2018.04.040_bib19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/bcr3336","article-title":"Hiding in plain view: the potential for commonly used drugs to reduce breast cancer mortality","volume":"14","author":"Holmes","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jss.2018.04.040_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/annonc\/mdu225","article-title":"Estimates of benefits and harms of prophylactic use of aspirin in the general population","volume":"26","author":"Cuzick","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jss.2018.04.040_bib21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","article-title":"Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials","volume":"13","author":"Algra","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jss.2018.04.040_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13058-017-0840-7","article-title":"Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study","volume":"19","author":"Clarke","year":"2017","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jss.2018.04.040_bib23","first-page":"1586","article-title":"Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer","volume":"11","author":"Johnson","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jss.2018.04.040_bib24","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/jnci\/djk132","article-title":"A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence","volume":"99","author":"Jacobs","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jss.2018.04.040_bib25","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/aje\/kwm195","article-title":"Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort","volume":"166","author":"Gill","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jss.2018.04.040_bib26","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1186\/s12885-015-1979-1","article-title":"Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer","volume":"15","author":"Kim","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jss.2018.04.040_bib27","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1200\/JCO.2009.22.7918","article-title":"Aspirin intake and survival after breast cancer","volume":"28","author":"Holmes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2018.04.040_bib28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10549-006-9277-x","article-title":"NSAID use and survival after breast cancer diagnosis in post-menopausal women","volume":"101","author":"Blair","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jss.2018.04.040_bib29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/bjc.2014.264","article-title":"Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study","volume":"111","author":"Fraser","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jss.2018.04.040_bib30","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/1471-2407-14-391","article-title":"Aspirin intake and breast cancer survival - a nation-wide study using prospectively recorded data in Sweden","volume":"14","author":"Holmes","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jss.2018.04.040_bib31","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10552-007-9003-y","article-title":"NSAIDs and breast cancer recurrence in a prospective cohort study","volume":"18","author":"Kwan","year":"2007","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.jss.2018.04.040_bib32","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1158\/1055-9965.EPI-11-1012","article-title":"Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jss.2018.04.040_bib33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3121\/cmr.2008.825","article-title":"Breast cancer subtypes based on ER\/PR and Her2 expression: comparison of clinicopathologic features and survival","volume":"7","author":"Onitilo","year":"2009","journal-title":"Clin Med Res"},{"key":"10.1016\/j.jss.2018.04.040_bib34","doi-asserted-by":"crossref","first-page":"djv048","DOI":"10.1093\/jnci\/djv048","article-title":"Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race\/ethnicity, poverty, and state","volume":"107","author":"Kohler","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jss.2018.04.040_bib35","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.2012.42.2006","article-title":"Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence","volume":"30","author":"Zhang","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jss.2018.04.040_bib36","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s10552-011-9769-9","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype","volume":"22","author":"Brasky","year":"2011","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.jss.2018.04.040_bib37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10549-014-3030-7","article-title":"Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women","volume":"146","author":"Cui","year":"2014","journal-title":"Breast Cancer Res Treat"}],"container-title":["Journal of Surgical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480418302774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022480418302774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T09:56:11Z","timestamp":1534154171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022480418302774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":37,"alternative-id":["S0022480418302774"],"URL":"https:\/\/doi.org\/10.1016\/j.jss.2018.04.040","relation":{},"ISSN":["0022-4804"],"issn-type":[{"value":"0022-4804","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of aspirin use on breast cancer subtype and clinical course","name":"articletitle","label":"Article Title"},{"value":"Journal of Surgical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jss.2018.04.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}